lung

Merck to Showcase Oncology Portfolio Advancements at ESMO 2023, Highlighting Key Cancer Treatment Breakthroughs

(IN BRIEF) Merck, a leading science and technology company, is set to present 28 abstracts at the 2023 European Society…

7 months ago

Roche: Phase III IMpower131 study met its co-primary endpoint of progression-free survival of people with a type of advanced squamous lung cancer

BASEL, 20-Mar-2018 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower131 study met its…

6 years ago

AstraZeneca: US FDA approval for Imfinzi for the treatment of patients with unresectable Stage III non-small cell lung cancer

Imfinzi is the only immunotherapy approved for patients with unresectable Stage III non-small cell lung cancer Imfinzi showed an 11.2…

6 years ago